Table 3.

Protection induced by transfer of anti-SEB antibodiesa

TherapyNo. live/no. dead after challenge with:
10 LD50100 LD50
0 h4 h10 h0 h4 h10 h
Eluate (specific)10/0b10/0b5/510/0b10/0b2/8
Unpurified SEBIGH10/0b9/1b1/97/3c4/6d0/10
Flowthrough0/100/10NDe1/90/10ND
Buffer0/100/10ND NDNDND
  • a Mice (10 per group) were challenged with 10 or 100 LD50 of SEB at the same time as the therapy, or therapy was initiated 4 or 10 h after toxin injection. A potentiating dose of LPS was given to mice 3 h after SEB injection. Mice were observed for 96 h after the challenge. Controls included age-matched mice that received LPS or SEB alone (no lethality was observed).

  • b P < 0.001 versus nonspecific flowthrough IgG.

  • c P = 0.02 versus nonspecific flowthrough IgG.

  • d P = 0.09 versus nonspecific flowthrough IgG.

  • e ND, not determined.